Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of maternal-fetal cytomegalovirus transmission with Cytotect CP Biotest
2020-002383-32Phase 3Completed
- Sponsor
- Biotest AG
- Start
- Mar 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of human cytomegalovirus immune globulin in congenital cytomegalovirus infection (cCMV) and cytomegalovirus disease (CMV), sponsored by Biotest AG. Primary endpoint: Overall rate of maternal-fetal CMV transmission at amniocentesis. Started Mar 2021; status: completed.
02
Drugs
human cytomegalovirus immune globulin
03
Conditions
congenital cytomegalovirus infection (cCMV)cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2020-002383-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002383-32.